Cargando…
Antagonism of Bcl-X(L) is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
BACKGROUND: BH3 mimetics are a class of drugs that antagonize the Bcl-2 family of apoptosis inhibitors. We have previously shown that these compounds can potentiate the activity of carboplatin against several ovarian cancer cell lines. However, recent clinical studies have highlighted that BH3 mimet...
Autores principales: | Abed, Mohammed Najim, Abdullah, Marwan Ibrahim, Richardson, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832520/ https://www.ncbi.nlm.nih.gov/pubmed/27080533 http://dx.doi.org/10.1186/s13048-016-0234-y |
Ejemplares similares
-
Antagonizing Bcl-2′s BH4 domain in cancer
por: Vervloessem, Tamara, et al.
Publicado: (2015) -
Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
por: Abdullah, Marwan Ibrahim, et al.
Publicado: (2017) -
Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death
por: Abdullah, Marwan Ibrahim, et al.
Publicado: (2019) -
Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014) -
BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)